Showing results (171-180 of 274) with videos related to
Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.Proteomics|September 16, 2003
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancerPaul C Herrmann, John W Gillespie, Lu Charboneau, et al.JAMA Network Open|October 27, 2021
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020Satya Das, Liping Du, Cody L Lee, et al.Cancer|January 3, 2013
Feasibility and safety of sequential research-related tumor core biopsies in clinical trialsJung-min Lee, John L Hays, Anne M Noonan, et al.Journal of the National Cancer Institute|April 10, 2025
A working group report from the 2024 NCI/GCSC endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy eraCasey M Cosgrove, Dmitriy Zamarin, Jose R Conejo-Garcia, et al.Frontiers in Medicine|June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination TrialsChanning J Paller, Erich P Huang, Thomas Luechtefeld, et al.Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work GroupR Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Cediranib for metastatic alveolar soft part sarcomaShivaani Kummar, Deborah Allen, Anne Monks, et al.Pageof 28